48 related articles for article (PubMed ID: 28393224)
1. Overexpression of p53 protein is a marker of poor prognosis in Mexican women with breast cancer.
Dimas-González J; Maldonado-Lagunas V; Díaz-Chávez J; López-Arellano ME; Muñoz-Camacho J; Terán-Porcayo MA; Lagunas-Martínez A
Oncol Rep; 2017 May; 37(5):3026-3036. PubMed ID: 28393224
[TBL] [Abstract][Full Text] [Related]
2. Carboxypeptidase A4 negatively correlates with p53 expression and regulates the stemness of breast cancer cells.
Wang Y; Xie Y; Niu Y; Song P; Liu Y; Burnett J; Yang Z; Sun D; Ran Y; Li Y; Sun L
Int J Med Sci; 2021; 18(8):1753-1759. PubMed ID: 33746592
[No Abstract] [Full Text] [Related]
3. Decitabine induces IRF7-mediated immune responses in p53-mutated triple-negative breast cancer: a clinical and translational study.
Wang H; Wang Z; Wang Z; Li X; Li Y; Yan N; Wu L; Liang Y; Wu J; Song H; Qu Q; Huang J; Chang C; Shen K; Chen X; Lu M
Front Med; 2024 Apr; 18(2):357-374. PubMed ID: 38157193
[TBL] [Abstract][Full Text] [Related]
4. Machine learning analysis identifies genes differentiating triple negative breast cancers.
Kothari C; Osseni MA; Agbo L; Ouellette G; Déraspe M; Laviolette F; Corbeil J; Lambert JP; Diorio C; Durocher F
Sci Rep; 2020 Jun; 10(1):10464. PubMed ID: 32591639
[TBL] [Abstract][Full Text] [Related]
5. Recurrent mutations in topoisomerase IIα cause a previously undescribed mutator phenotype in human cancers.
Boot A; Liu M; Stantial N; Shah V; Yu W; Nitiss KC; Nitiss JL; Jinks-Robertson S; Rozen SG
Proc Natl Acad Sci U S A; 2022 Jan; 119(4):. PubMed ID: 35058360
[TBL] [Abstract][Full Text] [Related]
6. The
Makuch-Kocka A; Kocki J; Brzozowska A; Bogucki J; Kołodziej P; Płachno BJ; Bogucka-Kocka A
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33673050
[TBL] [Abstract][Full Text] [Related]
7. Triple-negative breast tumors are dependent on mutant p53 for growth and survival.
Dibra D; Moyer SM; El-Naggar AK; Qi Y; Su X; Lozano G
Proc Natl Acad Sci U S A; 2023 Aug; 120(34):e2308807120. PubMed ID: 37579145
[TBL] [Abstract][Full Text] [Related]
8. Whole genome sequence analysis suggests intratumoral heterogeneity in dissemination of breast cancer to lymph nodes.
Blighe K; Kenny L; Patel N; Guttery DS; Page K; Gronau JH; Golshani C; Stebbing J; Coombes RC; Shaw JA
PLoS One; 2014; 9(12):e115346. PubMed ID: 25546409
[TBL] [Abstract][Full Text] [Related]
9. TP53
Su Y; Zhao J; Fu H; Liu Z; Du P; Zheng J; Wu J; Zhang J
Biochem Pharmacol; 2024 Mar; 221():116047. PubMed ID: 38331350
[TBL] [Abstract][Full Text] [Related]
10. Understanding the prion-like behavior of mutant p53 proteins in triple-negative breast cancer pathogenesis: The current therapeutic strategies and future directions.
Naeimzadeh Y; Tajbakhsh A; Fallahi J
Heliyon; 2024 Feb; 10(4):e26260. PubMed ID: 38390040
[TBL] [Abstract][Full Text] [Related]
11. Serological levels of mutated p53 protein are highly detected at early stages in breast cancer patients.
Balogh GA; Mailo D; Nardi H; Corte MM; Vincent E; Barutta E; Lizarraga G; Lizarraga P; Montero H; Gentili R
Exp Ther Med; 2010 Mar; 1(2):357-361. PubMed ID: 22993549
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of the p53 tumor suppressor gene product in primary lung adenocarcinomas is associated with cigarette smoking.
Westra WH; Offerhaus GJ; Goodman SN; Slebos RJ; Polak M; Baas IO; Rodenhuis S; Hruban RH
Am J Surg Pathol; 1993 Mar; 17(3):213-20. PubMed ID: 8434702
[TBL] [Abstract][Full Text] [Related]
13. Research insights into the chemokine-like factor (CKLF)-like MARVEL transmembrane domain-containing family (CMTM): their roles in various tumors.
Duan SL; Jiang Y; Li GQ; Fu W; Song Z; Li LN; Li J
PeerJ; 2024; 12():e16757. PubMed ID: 38223763
[TBL] [Abstract][Full Text] [Related]
14. TK1 expression influences pathogenicity by cell cycle progression, cellular migration, and cellular survival in HCC 1806 breast cancer cells.
Bitter EE; Skidmore J; Allen CI; Erickson RI; Morris RM; Mortimer T; Meade A; Brog R; Phares T; Townsend M; Pickett BE; O'Neill KL
PLoS One; 2023; 18(11):e0293128. PubMed ID: 38033034
[TBL] [Abstract][Full Text] [Related]
15. Novel Expression of Thymine Dimers in Renal Cell Carcinoma, Demonstrated through Immunohistochemistry.
Novacescu D; Cut TG; Cumpanas AA; Bratosin F; Ceausu RA; Raica M
Biomedicines; 2022 Oct; 10(11):. PubMed ID: 36359193
[TBL] [Abstract][Full Text] [Related]
16. Proteomics and its applications in breast cancer.
Neagu AN; Whitham D; Buonanno E; Jenkins A; Alexa-Stratulat T; Tamba BI; Darie CC
Am J Cancer Res; 2021; 11(9):4006-4049. PubMed ID: 34659875
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive Bioinformatics Analysis of mRNA Expression Profiles and Identification of a miRNA-mRNA Network Associated with the Pathogenesis of Low-Grade Gliomas.
Wang M; Cui Y; Cai Y; Jiang Y; Peng Y
Cancer Manag Res; 2021; 13():5135-5147. PubMed ID: 34234557
[TBL] [Abstract][Full Text] [Related]
18. Patient-Specific Network for Personalized Breast Cancer Therapy with Multi-Omics Data.
Cava C; Sabetian S; Castiglioni I
Entropy (Basel); 2021 Feb; 23(2):. PubMed ID: 33670375
[TBL] [Abstract][Full Text] [Related]
19. Over-expression of TOP2A as a prognostic biomarker in patients with glioma.
Zhou T; Wang Y; Qian D; Liang Q; Wang B
Int J Clin Exp Pathol; 2018; 11(3):1228-1237. PubMed ID: 31938217
[TBL] [Abstract][Full Text] [Related]
20. Association Between Genetic Variant in the Promoter of Pri-miR-34b/c and Risk of Glioma.
Li J; Liu X; Qiao Y; Qi R; Liu S; Guo J; Gui Y; Li J; Yu H
Front Oncol; 2018; 8():413. PubMed ID: 30319976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
